Sacubitril-valsartan Versus Usual Anti-hypertensives in LVAD
Status:
Withdrawn
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
This pilot, feasibility study evaluates the efficacy of sacubitril-valsartan (Entresto)
versus usual anti-hypertensive medications in patients with left ventricular assist devices
(LVAD). It also measures diurnal blood pressure variations in the context of continuous flow
physiology.
Phase:
Phase 4
Details
Lead Sponsor:
University of Maryland University of Maryland, College Park
Collaborator:
Medtronic
Treatments:
Antihypertensive Agents LCZ 696 Sacubitril and valsartan sodium hydrate drug combination Valsartan